Kornimate/medical-research-clean huggingface dataset:
pediatric type iii supracondylar humeral fracture

Conditions: Supracondylar Humerus Fracture; Pediatric Fractures

Summary: the purpose of this study was to compare pin configuration effects on early secondary displacement in the surgical treatment of pediatric supracondylar humeral fractures (schf).

the study consisted of 100 (68m, 32f) children who underwent surgery between 2010 and 2013 for gartland type 3 (schf). the patients divided into five groups according to the top in configurations (crossed 1 lateral 1 medial, crossed 2 lateral 1 medial, crossed 1 lateral 2 medial, 2 lateral divergent, and 3 lateral divergent). the average age at the time of injury was 7.34 (between 2 and 14 years). bauman angle (ba), humerocapital angle (hca), anterior humeral line (ahl), flexion range, extension range, and carrying angle (ca) were compared at preoperative, postoperative 1st-day, postoperative last control, and non-operated side. the mean follow-up time 24,96±11,06 with a range of 12-54 months.

Eligibility criteria:
inclusion criteria * pediatric gartland type 3 supracondylar humeral fracture * patients operated between 2010-2013 * patients under 16 years old exclusion criteria: * pathological fractures * conservative treated supracondylar fractures * less than the 1-year follow-up * patients with incomplete postoperative follow-up * patients older than 16 years * pediatric gartland type 1 and 2 supracondylar humeral fracture

Keywords: pediatric supracondylar humeral fracture k wires closed reduction pin configuration
are dental neglect and the siblings risk factors in children

Conditions: Behavior, Child; Caries,Dental; Neglect, Child; Anxiety

Summary: neglect insidiously affects a child's overall health in all aspects. the aim of this study was to determine whether the presence of siblings caused dental neglect, and whether there was a relationship between dental neglect and anxiety.

dental neglect is an intentional failure of parents or caregivers to take precautions and fulfil necessary dental treatment, and has a close relationship with dental caries and anxiety. oral health status of the children was evaluated using the dmft/dmft, pufa/pufa, and ohi-s indices. in addition, the parents completed the dental neglect scale (dns) and a questionnaire, and the modified child dental anxiety scale (mcdasf) was administered to the children to assess their dental anxiety.

Eligibility criteria:
inclusion criteria: * aged between 6 and 12 years old * being healthy * being volunteer for the study exclusion criteria: * systemic and mental disorders * syndromes or other major health diseases * cooperation problems

Keywords: anxiety siblings dental caries oral health child abuse
testosterone improves exercise oxygen uptake, insulin resistance and muscle strength in elderly patients with chronic heart failure

Conditions: Congestive Heart Failure

Summary: background: patients with congestive heart failure (chf) show muscle mass wasting and decreased testosterone levels. long-term testosterone supplementation improves walking distance and glucose metabolism of patients chf. no studies have investigated the integrated effects of testosterone on exercise oxygen uptake muscle strength and glucose metabolism in patients with chf regardless of the presence of hypogonadism. aim: to assess the effect of a 12 week testosterone administration on maximal exercise capacity, muscle strength and insulin resistance in elderly chf patients. methods: seventy elderly patients with stable chf, mean age 71 ± 8 years, ejection fraction 34 ± 1%, nyha class ii/iii 38/32, were enrolled. of these, 35 were randomized to receive testosterone therapy (through intramuscular injection every 6 week) and 35 to receive placebo both on top of maximal medical therapy. at baseline and after 12 weeks all patients underwent echocardiogram, cardiopulmonary test, 6-minute walking test (6mwt), quadriceps maximal isometric and isokinetic strength.


Eligibility criteria:
inclusion criteria: * left ventricular ejection fraction (lvef) \< 40%; * new york heart association (nyha) class ii or iii; * clinical stability without hospital admission for heart failure in the previous 3 months. exclusion criteria: * unstable angina or recent acute myocardial infarction, * history of severe liver diseases * history of severe kidney diseases * uncontrolled hypertension * erythrocytosis (hematocrit \> 50%) * hyperviscosity * prostate cancer, prostate-specific antigen (psa) greater than 3 ng/ml * severe lower urinary tract symptoms.

Keywords: to assess the effect of a 12 week testosterone administration on maximal exercise capacity, muscle strength and insulin resistance in elderly chf patients
factors increasing air burden in intravenous tubing

Conditions: Air Embolism; Air Leakage; Air Burden

Summary: there is widespread acceptance that air in intravenous (iv) fluid tubing (lines) can pose a significant risk to patients.1 a rigorous literature search regarding sources of this air identified only anecdotal and non-clinical work regarding the presence and sources of air in iv tubing. most published case studies have focused on air entrainment from accidental or inadvertent sources - empty iv fluid bags, incomplete priming of the tubing prior to infusion, and air-detection device failures, as examples. the sources (and volume) of air inside iv tubing during common surgical procedures or interventions have yet to be studied prospectively. understanding the frequency and magnitude of the presence of unintended air in iv tubing is the first step in devising potential avoidance strategies for eliminating unintended air in iv tubing. this study was designed to identify both the sources and magnitude of air that occurs in iv tubing during routine surgical procedures.

methods: an observational prospective trial was conducted in operating room settings across multiple study sites. 120 surgical patients undergoing a variety of interventional and surgical procedures were selected, representing multiple patient populations, case types and anesthesia setups. the clearline iv, a device that detects and removes air from iv tubing, was inserted into the iv circuit. clinicians followed standard protocols. blood warmers were used at the practitioner's discretion. iv fluid was administered at a constant flow rate or through a bolus given over 30-60 seconds per standard of care. the volume and duration of fluid administration was recorded, along with the frequency, duration and amount of air captured by clearline iv.

Eligibility criteria:
inclusion criteria: * any age - both pediatric and adult * weight equal to or greater than 5kg * surgical procedures * cardiac catherization procedures * minimum two hours procedure time exclusion criteria: * patient weight less than 5 kg * procedures not involving surgery or cardiac catherization * procedures less than two hours
experimental medication for the treatment of generalized anxiety disorder

Conditions: Anxiety Disorder

Summary: the purpose of this study is to determine whether an experimental anti-anxiety medication is effective in the treatment of generalized anxiety disorder.

protocol 04-001-01 the primary objective of the study is to assess, under controlled conditions, the safety and efficacy of an experimental anti-anxiety medication relative to placebo in subjects with generalized anxiety disorder (gad). the secondary objective of the study is to study algorithms for discontinuation of an experimental anti-anxiety medication. recruiting: participants are currently being recruited and enrolled.

Eligibility criteria:
inclusion criteria: * subjects 18 to 65 years of age will be eligible to participate if they satisfy the dsm-iv-tr criteria for the diagnosis of gad. exclusion criteria: * no other primary psychiatric diagnosis besides gad.

Keywords: double blind, placebo controlled, safety and efficacy generalized anxiety disorder
in-vivo activated t-cell depletion to prevent gvhd

Conditions: Acute Myelogenous Leukemia; Acute Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Chronic Lymphocytic Leukemia; Myelodysplasia; Lymphoma, Non-Hodgkin's; Mantle-Cell Lymphoma; Hodgkin's Disease; Multiple Myeloma; Myelofibrosis

Summary: the purpose of this study is to compare the effects (good and bad) of the medication basiliximab in combination with cyclosporine with cyclosporine alone for the prevention of graft-versus-host disease. this research is being done because there is no completely safe and effective prevention for graft-versus-host disease. it is known that cyclosporine helps with gvhd but we would like to know if the addition of basiliximab will decrease the incidence and/or severity of gvhd after a transplant known as nonmyeloablative ("mini" transplant).


Eligibility criteria:
inclusion criteria: * acute myelogenous leukemia, acute lymphocytic leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, myelodysplasia, non-hodgkin's lymphoma, mantle cell, hodgkin's disease, multiple myeloma, myelofibrosis with disease-specific eligibility requirements as outlined in the protocol * donor requirement: must have a fully hla-matched (10 of 10) related or unrelated donor, eighteen years of age or older, who is capable of undergoing gcsf mobilization and apheresis. exclusion criteria: * active cns disease (the presence of leukemic blasts in the csf) * pregnancy or breast-feeding * sgot \>3x upper limit of normal * creatinine \>2 or creatinine clearance \<50cc/hr. * fractional shortening by echocardiogram not within normal limits per institution * pulmonary function: dlco less that 50% of normal predicted, corrected for anemia * prior allogeneic transplant
effect of orofacial myofunctional therapy on mouth air leak in patients with sleep apnea treated with cpap

Conditions: OSA; Apnea+Hypopnea

Summary: to verify the effect of orofacial myofunctional therapy in patients with osa during the use of cpap with a nasal mask, on the frequency and leak flow. in addition, the impact on mouth opening frequency, sleep quality, perception of excessive daytime sleepiness, and cpap adherence will be evaluated.

the use of continuous positive airway pressure (cpap) with a nasal mask during sleep is the gold standard treatment for moderate to severe obstructive sleep apnea (osa). however, low adherence to cpap is the main limiting factor in clinical practice. recent studies suggest that unintentional air leak through the mouth contributes significantly to poor adherence to cpap. orofacial myofunctional therapy (omt) is effective for treating mild to moderate osa and has not been tested in patients with mouth air leaks. osa patients using nasal cpap and mouth air leaks will be recruited and will use the standard cpap model and nasal mask during the first and last week of the study to record adherence and home leak. patients will be treated by performing daily (3 times a day) orofacial myofunctional exercises aimed at strengthening the muscles of the oral cavity. exercises will be supervised weekly for 3 months. all patients will undergo at the beginning and end of treatment: polysomnography with cpap and nasal mask, speech-language pathology assessment adequated for osa (scores ranging from 0 to 241, with higher values indicating greater dysfunction), quality of life questionnaire, and nasosinusal symptoms (snot -22), sleep quality (pittsburgh) and sleepiness (epworth). polysomnography will include a pneumotachograph (hans rudolph) in the cpap circuit to record flow and a magnetic jaw movement sensor (brizzy) to record the episodes of mouth opening. the mouth air leak episodes were considered when they exceeded 20% above baseline (intentional leak with the mask fitted and mouth closed at the beginning of the psg examination with cpap) for a minimum of 10 seconds. leaks ending with arousal or full awakening were considered arousal or full awakening associated with mouth air leak. mouth opening during the leak episodes was determined by the difference between the amplitude at the end of the leak and the amplitude during the leak. our hypothesis is that the orofacial myofunctional therapy will reduce mouth leakage in osa patients treated with cpap and nasal mask.

Eligibility criteria:
inclusion criteria: • diagnosis of osa (ahi\>15 events/h) on use of cpap (\>3 months) with suspect mouth leak as observed by the complaint of morning dry mouth and or cpap report indicating an excessive air leak exclusion criteria: * central sleep apnea, oxygen dependent, copd.

Keywords: orofacial myofunctional therapy oropharyngeal exercises cpap nasal mask air leak sleep apnea
the treatment of bioartificial liver with hihep cells after extensive hepatectomy

Conditions: Hepatoma Resectable

Summary: it is a prospective, non-randomized, single-arm cohort study. a total of 10 patients will be included in this study. based on standardized treatment, the treatment of bioartificial liver device will be applied 48-72 hours after extensive hepatectomy. in order to evaluate the security and effectiveness of the device, liver function, liver volume, the incidence of liver failure and other results will be analyzed.

include large-scale hepatectomy patients who meet the inclusion criteria into the experimental group. patient will be sent to icu monitoring after surgery , the investigators will evaluate the blood routine, liver and kidney function, blood coagulation function, and immune inflammation indicators on the first day after surgery, and large veins will be temporarily indwelled within 48-72 hours hemodialysis tube, then take artificial liver treatment which lasts 4-6h, follow-up test results on the 1st day, 3rd day, 7th day, 1 month and 3 months about blood routine, liver and kidney function, coagulation function, blood ammonia, immune inflammation indicators, imaging examinations (ct or mr) at 7 days, 1 month and 3 months after treatment, to evaluate the recovery of liver function and liver regeneration after artificial liver treatment.

Eligibility criteria:
inclusion criteria: 1. diagnosed as liver cancer, hepatolithiasis, benign liver tumor, with clear indications for liver resection; 2. liver function child a-b; 3. there is no contraindication to surgery for cardiopulmonary function; 4. the expected remaining liver volume/standard liver volume is less than 50%; exclusion criteria: 1. in the late stage of the disease, patients with frequent symptoms such as cerebral edema accompanied by cerebral herniation and clinical evidence indicating intracranial hemorrhage; 2. pao2/fio2 is less than 200 and cannot be corrected; 3. patients with diffuse intravascular coagulation; 4. those with active bleeding; 5. uncontrolled infection; 6. the platelet count is less than 50,000/μl and cannot be corrected; 7. there is no blood vessel available for dialysis treatment; 8. hiv, hdv or hcv positive; 9. drug abuse within 1 year; 10. those with severe systemic circulatory failure; 11. those who are highly allergic to the drugs used in the treatment process, such as plasma, heparin, protamine, etc.; 12. combined pregnancy; 13. patients with hepatorenal syndrome; 14. patients with autoimmune liver disease; 15. patients with non-alcoholic fatty liver and hereditary liver diseases (wilson syndrome and a-antitrypsin deficiency); 16. other conditions that the clinician believes cannot tolerate the treatment.
safety and efficacy of bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir + emtricitabine/tenofovir disoproxil fumarate in treatment naive, hiv-1 and hepatitis b co-infected adults

Conditions: HIV-1/HBV Co-Infection

Summary: the primary objective of this study is to evaluate the efficacy of fixed-dose combination (fdc) of bictegravir/emtricitabine/ tenofovir alafenamide (b/f/taf) versus dolutegravir (dtg) + emtricitabine/tenofovir disoproxil fumarate (f/tdf) in treatment-naïve and hiv-1 and hepatitis b virus (hbv) adults.


Eligibility criteria:
key inclusion criteria: * human immunodeficiency virus type 1 (hiv-1) co-infection: * must be hiv antiretroviral treatment naive with plasma hiv-1 ribonucleic acid (rna) ≥ 500 copies/ml at screening * ≤ 10 days of prior therapy with any antiretroviral agent, including lamivudine and entecavir, following a diagnosis of hiv-1 infection (except the use for pre-exposure prophylaxis (prep) or post-exposure prophylaxis (pep), up to one month prior to screening) * screening genotype report must show sensitivity to emtricitabine (ftc) and tenofovir (tfv). this report will be provided by gilead sciences. alternatively, if genotype results from a local laboratory obtained ≤ 90 days prior to screening visit date show sensitivity to these drugs, this genotype will be acceptable to fulfill this inclusion criterion in the event that the genotype obtained at screening is not yet available and all other inclusion/exclusion criteria have been confirmed * hbv co-infection: * must be hepatitis b virus (hbv) treatment naive (defined as \< 12 weeks of oral antiviral treatment) * screening hbv deoxyribonucleic acid (dna) ≥ 2000 iu/ml * hepatic transaminases (aspartate aminotransferase (ast) and alanine aminotransferase (alt)) ≤ 10 x upper limit of normal (uln) * total bilirubin ≤ 2.5 x uln key exclusion criteria: * hepatitis c virus (hcv) antibody positive and hcv rna detectable * individuals experiencing decompensated cirrhosis (eg, ascites, encephalopathy, or variceal bleeding) or with child-pugh-turcotte (cpt) c impairment * current alcohol or substance use judged by the investigator to potentially interfere with study compliance * active, serious infections (other than hiv-1 and hbv infection) requiring parenteral antibiotic or antifungal therapy within 30 days prior to day 1 * participation in any other clinical trial, including observational studies, without prior approval from the sponsor is prohibited while participating in this trial note: other protocol defined inclusion/exclusion criteria may apply.
contribution of the sonication of implants to the diagnosis of joint prosthesis infection: a retrospective cohort study

Conditions: Prosthesis Related Infection

Summary: studies on sonication suffer from a heterogeneity which makes their analysis complex, due to the absence of a gold standard allowing positive cases to be defined unequivocally. thus, the sensitivity of the technique has been assessed on cases defined in different ways, which makes the studies difficult to compare (number of samples taken, number of positive samples, variable duration of culture, etc.). it should nevertheless be noted that the majority of the series conclude with a higher sensitivity than that of standard samples, in particular in the event of a strain with difficult growth (cutibacterium acnes, deficient streptococci) or in the event of prior antibiotic therapy. in the absence of a comparative reference allowing to conclude on the intrinsic performances of sonication as a diagnostic test, it seems interesting to evaluate its contribution in current practice, in particular in the difficult cases where the standard culture does not make it possible to fulfill the criterion. major (zero or only one positive sample). to the knowledge of the investigators, there is no study of this kind, which could make it possible to specify the place of this technique in the diagnostic procedure and to improve the care of patients.


Eligibility criteria:
inclusion criteria: * adult patients (age ≥18 years) * have been hospitalized and operated on for a change of hip or knee joint prosthesis between 01/01/2019 and 07/31/2022 * have had at least 3 samples taken for microbiological purposes, pre- or intraoperatively * the explanted prosthesis must have been analyzed by sonication. * not opposing the reuse of its data for scientific research purposes exclusion criteria: - opposition of the patient to the reuse of his data.

Keywords: prosthesis related infection joint prosthesis infection sonication of implants cutibacterium acnes streptococci
family and web-based nutrition intervention to increase vegetable, fruit, and dairy intakes in children

Conditions: Diet Habit

Summary: considering the high prevalence of childhood obesity worldwide, effective interventions are needed . parental involvement in interventions and the use of web-based modalities appear to be promising approaches. the aim of the study was to evaluate the efficacy of an innovative family and web-based nutrition intervention called "family nutriathlon" on consumption of vegetables and fruit and dairy products and/or alternatives and on diet quality among children and their parents.

forty-three families, with at least one child with a bmi \>85th percentile, participated in either the intervention (n=24) or control group (n=19) over an 8-week period. families in the intervention (family nutriathlon) will participated in a nutrition challenge that aimed to increase their consumption and variety of fruits and vegetables and dairy products by recording their daily intakes using a web-based platform. families in the control group received recommendations based on general nutrition guidelines. three follow-ups with a dietitian once every two weeks via skype to assess progress were scheduled. a three-day food record was completed at baseline (week 0), immediately after (week 8) and 6 months after the intervention. a two-way repeated measures analysis of variance was used to assess changes in consumption of fruits and vegetables and dairy products, diet quality and dietary intakes between groups and over time.

Eligibility criteria:
all inclusion/exclusion criterion were the same between the two projects (including the intervention) except for the inclusion of a child living with obesity or overweight. children were aged between 8 and 16 years, but there was no age limit for parents.

Keywords: vegetables, fruits, dairy, children, habits